About This Deal

Gilead Sciences acquired MiroBio Ltd. for $414 million cash, a transaction announced in September 2022.

Acquired the privately-held U.K. biotechnology company focused on restoring immune balance with agonists targeting immune inhibitory receptors, for $414 million in cash. Accounted for as an asset acquisition.

Acquired the privately-held U.K. biotechnology company focused on restoring immune balance with agonists targeting immune inhibitory receptors, for $414 million in cash. Accounted for as an asset acquisition.

Deal Terms

Acquirer
Gilead Sciences
Target
MiroBio Ltd.
Value
$414 million cash
Date
September 2022
Type
Full acquisition
Status
Completed

Transaction Details

Announced
September 20, 2022

Advisors

Advisory firms were not disclosed for this transaction.

Related Deals & Entities

Sources: Press release ↗

See how Top Bucket AI works for your firm

Request Demo
Top Bucket AI Research

Stay ahead of private markets

Research and market intelligence for private-markets professionals.

✓

You're subscribed.

Thanks for signing up.